Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Sarcoma, Ewing 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1

Interventions

Cyclophosphamide 14fludarabine 8Rituximab 6Specimen Handling 5Magnetic Resonance Spectroscopy 5Vincristine 4Doxorubicin 4Dexamethasone 4zanubrutinib 3Prednisone 3Nivolumab 3Etoposide 3tazemetostat 2tafasitamab 2pirtobrutinib 2pembrolizumab 2glofitamab 2etoposide phosphate 2cemiplimab 2acalabrutinib 2Leukapheresis 2Immunotherapy, Adoptive 2Immunoglobulin G 2Gemcitabine 2Disulfides 2Cisplatin 2Cell- and Tissue-Based Therapy 2Biopsy 2venetoclax 1varlilumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × etoposide phosphate × 30 days × Clear all
NCT06954805 2026-05-27

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Columbia University

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

NCT06230224 2026-05-11

OLYMPIA-4

Regeneron Pharmaceuticals

Phase 3 Active not recruiting
216 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡